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resumo No decurso dos últimos 10 anos, a Indústria Farmacêutica (IF) tem estado sob
grande escrutínio por parte das Agências Regulamentares, profissionais de
saúde e doentes no geral, sobretudo por ter sido criticada no passado pelas
suas táticas de marketing e vendas agressivas e comportamento não ético. 
De forma a aumentar a transparência tanto das atividades desenvolvidas como
da sua relação com os médicos, a Indústria alterou significativamente a forma
como desenvolve e promove os medicamentos e dispositivos médicos. Muitas
destas alterações levaram a uma maior responsabilização dos Assuntos
Médicos (AM) na informação prestada à comunidade de prestadores de
cuidados de saúde sobre o perfil de segurança e o uso apropriado dos
medicamentos de uma empresa farmacêutica. Adicionalmente, verifica-se uma
tendência para limitar significativamente o acesso dos delegados de
informação médica aos prescritores, que tradicionalmente eram o veículo de
informação da Indústria, substituindo-os por colegas imparciais especializados
nos medicamentos (os colegas de Assuntos Médicos). 
Grande parte desta atividade informativa envolve estabelecer e desenvolver
relações de longa duração com líderes de opinião numa determinada área
terapêutica de interesse. Estas parcerias científicas são cruciais para a
melhoria dos resultados em saúde que as companhias farmacêuticas
pretendem alcançar. 
Os métodos utilizados pelos AM para comunicar ciência são diversos,
abrangendo publicações em jornais com revisão por pares, congressos,
sessões de educação médica contínua e grupos de discussão. Recentemente,
os meios digitais passaram a ser também mais utilizados para envolver
profissionais de saúde e doentes nesta partilha científica.   
Os AM impactaram significativamente o relacionamento com os clientes e
continuam a construir uma relação de confiança e valor, de transparência, de
discussão franca sobre benefícios e riscos e promovendo um diálogo
clinicamente robusto entre pares. 
A atividade dos AM, que ajuda a colmatar as necessidades dos doentes e 
médicos e promove o uso correto dos medicamentos, contribuirá para 
melhorar a reputação da IF. 
keywords Medical Affairs, Pharmaceutical Industry, medicines.
abstract Over the last 10 years, the Pharmaceutical Industry has been under great
scrutiny from regulators, healthcare professionals (HCPs) and patients in
general, as in the past it was criticized for the use of aggressive sales and
marketing tactics and unethical behaviour. 
To increase the transparency on the activities developed and its relationship
with physicians, it has undergone significant changes in the way that it
develops and markets medicines and medical devices. Many of these changes
have led to an increase in the responsibility of Medical Affairs to inform the
healthcare professionals’ community on the safe and appropriate use of the
company´s medicines. Additionally, there is a trend to greatly limit physician
access to traditional sales representatives who traditionally were industry’s
vehicle of information and replace them by unbiased subject matter experts, the
Medical Affairs colleagues. 
Much of this communication activity involves engaging and developing long-
term relationships with key scientific opinion leaders in the disease area of
interest. These scientific partnerships are crucial for the improvement of health
outcomes that the pharmaceutical companies aim to achieve.  
The methods used by Medical Affairs to communicate the science vary from
manuscripts in peer-reviewed journals, to congresses, continuous medical
education meetings and discussion groups. More recently, digital channels
have also been more frequently used to engage HCPs and even patients in this
scientific exchange. 
Medical Affairs have significantly impacted the relationship with customers,
continuing to build trust and value, transparency in all engagements, providing
a balanced discussion of benefits and risks, and leveraging clinically robust
dialogues on a peer-to-peer level.  
Medical Affairs activity, helping to address patients and physicians’ needs and
promoting the appropriate use of medicines, will contribute to improve the
reputation of the pharmaceutical industry.
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I – INTRODUCTION 
 
Traditionally, pharmaceutical industry model includes two main pillars: a R&D group 
in charge of developing new medicines/medical devices and a commercial team in 
charge of marketing and selling those products. However, over the past decade, the 
pharmaceutical industry has been under great scrutiny by regulatory authorities, with 
stricter legislation and frequent inspections and audits, as well as under market pressure 
to produce new medicines more rapidly.  
 
Despite these many changes, all the stakeholders continued to demand that high levels 
of scientific rigor should be maintained across the industry and in its interactions with 
healthcare professionals. As a consequence of this, the urge to create Medical Affairs 
teams was renewed. 
 
Medical Affairs originally appeared due to the need of having non-promotional, 
unbiased scientific communication to healthcare professionals, clearly independent from 
the commercial functions, while maintaining a bridge between research and 
development (R&D) and commercialization. Consequently, Medical Affairs has become 
an independent department/division, within the Medical Department. 
 
In the past, pharmaceutical companies considered Medical Affairs just a support 
function, and one that could even slow down marketing and commercial activities. 
Nowadays, this point of view is completely obsolete and as, for instance, Sales teams 
are shrinking, Medical Affairs teams are assuming new responsibilities and generating a 
real competitive advantage. They are now in charge of providing scientific and clinical 
expertise to support approved medicines, and working closely in the development of 
new drugs as early as phase 2 studies and throughout post approval activities. 
 
Furthermore, in a fast moving market environment, dynamic, innovative, engaging, and 
skilled Medical Affairs teams are better prepared to respond to customer demands and 
to develop and maintain stronger long-term relationships with key opinion leaders, 
scientific societies, payers and patient groups. All of this while keeping a link between 
R&D and commercial areas and focusing on the internal customer. 
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II – THE MEDICAL DEPARTMENT 
 
The objective of all pharmaceutical companies is to discover, develop and 
commercialize medicines with favorable risk/benefit ratio, which benefits the patients 
and are profitable to the company. To ensure that this happens, it is critical to have a 
medical and scientific oversight since early stages of drug development and up to loss 
of exclusivity. The Scientific Director provides this governance within the company. 
 
Every pharmaceutical company has a Scientific Director. Usually this person holds a 
degree of Medicine (doctor of medicine – MD) although a degree in pharmacy (doctor 
of pharmacy – PharmD) is also feasible, although less common. Nevertheless, due to 
the diversity and complexity of the activities developed by a pharmaceutical company, 
and the need to provide adequate support to several areas in a cross-functional way, a 
Medical Department is often put in place. Its dimension is usually adjusted to the size of 
the company, whether it is a multinational or a small biotechnological one. Even the 
way it is organized varies, and it can assume a horizontal, vertical or mixed hierarchical 
structure, with simple or complex lines of reporting. It greatly depends on cultural 
issues and different regulatory settings across countries. 
 
The major areas of responsibility for the Medical Department are to: 
 Provide a medical perspective and support to the development of new medicines 
(collaborating since the early phases up to phase IV clinical studies); 
 Provide the medical input necessary to support marketed medicines throughout 
their life cycle; 
 Provide specialized medical expertise, as required; 
 Contribute to implementation of regional and local product strategies; 
 Ensure the compliance with all applicable legal requirements, standard operating 
procedures and guidelines; 
 Ensure that the overall drug safety reporting process fully adheres to applicable 
requirements; 
 Perform internal audits and quality reviews; 
 Identify risks from a medical point of view and implement risk management 
activities; 
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 Develop educational activities (for internal and external customers); 
 Review promotional, educational and corporative materials; 
 Act as the ethical conscience of the company; 
 Act on behalf of the company next to Regulatory and Health Authorities, 
healthcare professionals and other external stakeholders; 
 
Usually the Medical Department is staffed with the following key players: 
 Medical Director; 
 Clinical research specialists; 
 Medical information specialists; 
 Medical/scientific advisors and medical science liaisons (Medical Affairs team) 
 Regulatory affairs specialists; 
 Drug safety/pharmacovigilance specialists 
 
The Medical Department is headed by the Medical Director (usually a physician), who 
leads a team of other physicians, pharmacists or life scientists and administrative staff. 
They all play an important role supporting all phases of a medicine life cycle, from early 
stages of development until the loss of exclusivity (LOE), always partnering with 
commercial colleagues. 
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III – IMPORTANCE AND ROLE OF MEDICAL AFFAIRS 
 
Medical Affairs is a global function. Nevertheless, Global Medical Affairs has a very 
limited role in country or region-specific activities because issues and regulations differ 
across markets. Global Medical Affairs defines a broad overall strategy and ensures that 
the activities across markets are aligned and that redundant efforts are avoided. It may 
also take the lead on activities that can truly span all markets, such as: 
 publication planning; 
 fostering long-term relationships with internationally recognized key opinion 
leaders; 
 draw general guidelines for selecting which studies to fund (company owned or 
from investigator-initiative research); 
 defining real-world data and outcome research needs; 
 global advisory board. 
 
Because Medical Affairs works closely with both scientific and commercial leaders 
within a pharmaceutical company, the function could be positioned under either Global 
Commercial or Global Development.  
 
However, as regulatory scrutiny has increasingly highlighted the need for a clear 
separation of commercial and educational/scientific activities, Global Medical Affairs 
has been generally aligned with Development (or sometimes in a direct reporting 
relationship to the CEO of a pharmaceutical company. It is also becoming more 
common for Medical Affairs to derive its budget from Drug Development rather than 
from Marketing. 
 
As mentioned previously, Medical Affairs is a division within the Medical Department. 
It typically interacts with many different players, both internal and external.  Regarding 
internal customers, it interacts with marketing, regulatory affairs, clinical research, 
medical information, pharmacovigilance, quality & compliance, access, sales, and legal. 
Considering external customers, the Medical Affairs team establishes straight, peer-to-
peer interactions between collaborators from the pharmaceutical company and 
healthcare professionals, mainly physicians, scientific societies and payers. 
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In larger pharmaceutical companies, reporting to the Medical Director, there can be also 
a Medical Affairs Lead/Director. This person usually has a degree in medicine (MD) 
although a degree in pharmacy (PharmD) is not uncommon. Apart from the director, 
Medical Affairs typically are staffed with medical managers/advisors and scientific 
advisors (both office based) and medical science liaisons – MSLs (who are field based), 
both of which are customer facing roles, but at different extents.  
 
Regarding the scientific background of people working in Medical Affairs (usually 
MDs, PharmDs, or holding any advanced master degree in life sciences), these are 
highly differentiated employees with in-depth knowledge of the therapy area, the 
relevant medicines in the company portfolio and its pipeline, capable of dealing with 
extremely complex scientific/technical information, which enables them to understand 
and effectively communicate the science behind a medicine or medical device. 
 
Considering that a drug emerging from clinical development and on route to enter 
commercialization may be, to a considerable extent, “unknown” to potential prescribers 
and other healthcare professionals, Medical Affairs spearheads efforts to explain the 
“real world” utility of this new drug through the dissemination of unbiased clinical and 
scientific information about it. Although Medical Affairs has traditionally focused on 
communications with healthcare professionals (people who make use of the drug), 
nowadays this information is increasingly important to payers as well (Governments, 
Health Ministries, Hospital Boards, insurance companies, etc). 
 
Internally, Medical Affairs often serves as a “bridge” between the research/clinical 
development and commercial divisions of a pharmaceutical company (or of a 
biotechnology company with in-house commercial capabilities), synthesizing 
information and translating findings about a drug into language accessible to company 
professionals whose primary expertise is not necessarily scientific. 
 
Overall, the responsibilities of a Medical Affairs team may include: 
 Perform in-country clinical studies feasibilities. Countries are often challenged 
about their capability to run clinical studies and Medical Affairs’ in-depth 
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knowledge of the national clinical setting and reality allow them to rapidly 
identify potentially interested centers and investigators. 
 Conducting non-registrational (typically Phase IV) clinical studies. After a drug 
wins EMA approval, Medical Affairs often assumes much of the responsibility 
for any additional clinical studies. Because these studies do not support the 
application for approval, they are known as non-registrational studies. 
 Medical Affairs also supports investigator-initiated studies. Medical Affairs 
reviews the clinical study proposals submitted by independent investigators and 
decides based on their scientific merits, which of the studies should receive 
financial support. 
 In addition to non-registrational studies, Medical Affairs is sometimes 
responsible for executing health economics and outcomes studies, in partnership 
with the Access department. These studies, which evaluate the impact of a drug 
use on such variables as overall medical costs and patient quality of life, can be 
used to “make the case” with health plans and prescribers that a drug’s value 
(financial and humanistic) exceeds its cost. 
 Medical Affairs may also be responsible for supporting the Brand team in 
formulating product messages.  Insights from Medical Affairs help Brand teams 
to develop clear and scientifically accurate promotional materials. They also 
develop and/or review scientific/medical content that is converted into training 
materials, for use with the Sales, Marketing, and enabling functions teams. 
 In the course of its outreach to the medical community, the Medical Affairs team 
learns a great deal about the market environment for company products and can 
share this knowledge with internal leaders, such as, product messages that are 
responsive to the concerns of prescribers and other key stakeholders. 
 Medical Affairs also plays an important role in disseminating written 
information to the scientific community. One major contribution of Medical 
Affairs in this area is defining the publication plan for each product. It also 
coordinates clinical and scientific communications disseminated by the company 
at medical congresses. 
 Members of the Medical Affairs “field force”, commonly called Medical 
Science Liaisons, are responsible for outreach to key opinion leaders (KOLs) —
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often the foremost researchers in their fields of expertise. KOL insights and 
involvement are often critical to development of a successful product.  
 Medical Affairs may sponsor (or lead the development of the sponsorship 
strategy for) external education programs for healthcare professionals, 
particularly in areas of focus within the company product portfolio. 
 Another core activity of the Medical Affairs function is to respond to unsolicited 
product inquiries from healthcare professionals and (to a lesser extent) patients.  
The volume of calls is highest around the time of the market launch of a new 
drug or following a major change in a drug’s approved prescribing information. 
 Medical Affairs is also important to help identify new business opportunities, 
unmet scientific/medical/patient needs and to contribute to challenge the status 
quo and suggest improvement actions, both for internal or external customers. 
 
In conclusion, the role of Medical Affairs within a pharmaceutical company serves to 
spearhead the dissemination (and in some cases the generation) of unbiased clinical and 
scientific information about a medicine (to be launched or already on the market) to the 
healthcare community and to offer medical and scientific expertise to support the Brand 
teams. In the course of executing these duties, members of the Medical Affairs team 
gather a great deal of market intelligence. Those findings are shared internally with 
senior management (in country and above country). 
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IV – CLOSER LOOK AT MEDICAL AFFAIRS 
 
The nine major responsibilities of Medical Affairs in a pharmaceutical company 
include: 
 
 
a) Product research and development 
 
The nature of Medical Affairs involvement in product research and development varies 
by stage of the product life cycle.  The involvement of Medical Affairs in development 
of a drug that has not yet been approved for marketing by EMA is typically modest 
compared to its role once EMA approval has been granted.  Its earlier contributions can, 
however, have a major impact. 
 
For instance, during the preclinical phase of drug development, Medical Affairs 
provides valuable perspective based on its understanding of alternative products and 
unmet needs. This insight can help produce a drug that addresses limitations in the 
current standard of care. 
 
Medical 
Affairs
Supporting 
product 
research & 
development Supporting 
investigator-
initiated 
studies
Executing 
health 
economics 
and 
outcomes 
studies
Supporting 
the Brand 
team
Spearheading 
publication 
planning
Cultivating 
long-term 
relationships 
with KOLs
Sponsoring 
external 
education 
programs
Supporting 
internal 
training 
programs
Response to 
unsolicited 
information 
requests
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Regarding resource allocation, phases III and IV are the major responsible for resource 
consumption, which typically corresponds to the peri-launch period of a medicine. 
 
The Medical Affairs team can help other stakeholders explore pivotal questions 
including:  
 What is the target population for the product?  Adult, pediatric, geriatric?   
 What is the relative importance of various product characteristics? Is there any 
trade-off to be made (e.g. dosing regimens)? 
 Is it important that a drug has a particular mode/route of administration? 
 Is it important that a drug reduces the incidence of a particular adverse event, 
such as nausea? 
 
Clinical development conducts all the clinical studies that directly support the product’s 
label for marketing approval. These are called registrational studies, because they gather 
the data upon which EMA makes its approval decision. They include Phases I, II, and 
III clinical studies. 
 
The assistance Medical Affairs provides during these studies is primarily related to 
identification and recruitment of study investigators. Its “field force” of MSLs can 
leverage contacts among key opinion leaders at the forefront of clinical research in 
order to aid investigator and site recruitment efforts. The Medical Affairs team may also 
continue to provide input regarding desirable product attributes from a prescriber and 
patient perspective. 
 
After a drug has won regulatory approval, Medical Affairs often assumes responsibility 
for subsequent clinical studies. Because these post-approval studies, also referred to as 
post-marketing or Phase IV studies, are not the basis for regulatory approval, they are 
considered non-registrational. These studies are typically large and community-based.   
 
They may also be observational in nature, that is, they track the clinical status of 
patients who have been prescribed a drug, without intervening in treatment. Although 
the primary focus for most Medical Affairs departments is Phase IV studies, in some 
pharmaceutical companies they may also assume primary responsibility for what are 
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known as Phase III B studies (those conducted after a submission to regulators for 
marketing approval and aiming an additional indication/label).  
 
There are a number of reasons to conduct non-registrational studies to supplement the 
information that formed the basis for EMA approval.  These reasons include:  
1) Gathering additional safety information.  
 As Phase III studies often include selected patients due to its strict 
inclusion criteria, once a new drug is on the market Phase IV studies are 
important to assess safety in a larger population, in specific 
subpopulations, or simply across a longer time span. Such information 
may be considered particularly important when a product has been 
granted accelerated approval to expedite patient access to an urgently 
needed therapy. This form of post-launch safety surveillance can detect 
rare adverse events and help clarify the frequency with which known 
adverse events occur. 
 
2) Enhancing product differentiation.  
 Non-registrational studies also gather additional information related to 
product differentiation. The clinical data submitted for EMA approval, 
does not usually demonstrate the product’s full therapeutic value and its 
areas of distinction from competitors.  A Phase IV study may supplement 
available data by, for instance, assessing results in a specific user 
segment to evaluate whether outcomes within that subpopulation are 
superior to outcomes in the broader population for which the drug is 
indicated. 
 
3) Evaluating product use in a variety of “real-world” settings.  
 The subjects in registrational studies whose behavior is carefully tracked 
under the ideal conditions of a clinical study may behave differently than 
people taking the commercialized drug would.  Phase III B and Phase IV 
studies can yield practical data about patient response when the drug is 
prescribed in a more typical setting, such as a routine physician office 
visit. One question might be, “is compliance with the recommended 
A CLOSER LOOK AT MEDICAL AFFAIRS 
 
Pedro Godinho (2014)   11 
treatment high or low?”  These studies are also an opportunity to gather 
additional outcomes data for analysis by the Health Economics and 
Outcomes group. Such studies also introduce the product to new 
prescribers who might not otherwise become aware of its benefits to their 
patients. 
 
4) Increasing local market presence and experience.  
 In addition to gathering information related to “real-world” use, non-
registrational studies may also be leveraged to increase local market 
presence. A pharmaceutical company may choose to replicate a global 
study in a local market. Such studies can both confirm a product’s 
efficacy and safety and provide local investigators who were not part of 
the global study an opportunity to participate in a product-related study.  
These studies may also permit comparison of the drug’s performance to 
the standard of care in that particular market. 
 
In most pharmaceutical companies, Medical Affairs focuses mainly on Phase IV post-
marketing studies of approved indications, while Clinical Development executes other 
clinical studies. In some instances, Medical Affairs may also be involved in the ongoing 
evaluation of new opportunities for drug use, which are “off-label” studies. The term 
“off-label” can encompass any change to the regulator-approved language regarding use 
of a drug, up to an entirely new indication.   
 
If results from an off-label study of a new indication are sufficiently promising, a 
pharmaceutical company may make the very large investment required to execute 
additional Phase II and Phase III studies in order to obtain regulatory approval.  Clinical 
Development is likely to assume responsibility for this new cycle of Phase II/III studies. 
 
Promotional use of the information gathered during off-label studies is prohibited. 
Medical Affairs colleagues can, however, provide some information about off-label 
studies in a reactive way, upon unsolicited request by a healthcare professional. 
Additionally, pharmaceutical companies are under a duty to publish their findings in 
peer-reviewed journals, so that both positive and negative data are available and 
effectively disclosed to the scientific community. 
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Phase IV studies initiated by a pharmaceutical company may be driven by interest in 
gathering additional product information or by a mandate by regulators to gather 
additional safety data. Investigator-initiated studies are typically smaller in scope. Their 
impetus is the interest of a leading physician or group of physicians in a new treatment 
approach, or a variation in some standard part of a drug therapy, such as a route of 
administration, dose, or dosing schedule. To help them make more informed prescribing 
decisions, some physicians may want to evaluate how different therapies perform “head 
to head.” 
 
 
b) Investigator-initiated studies 
 
Phase IV studies initiated by a pharmaceutical company may be driven by interest in 
gathering additional product information or by a mandate by regulators to gather 
additional safety or real-world data. Investigator-initiated studies are typically smaller in 
scope. Their motivation is the interest of a leading physician or group of physicians in a 
new treatment approach, or a variation in some standard part of a drug therapy, such as 
a route of administration, dose, or dosing schedule. To help them make more informed 
prescribing decisions, some physicians may want to evaluate two different therapies 
“head to head.” 
 
In investigator-initiated studies, the physicians proposing the study are responsible for 
the study conduct, the integrity of study findings, and adverse events reporting.  
Investigators will sometimes request support for their clinical studies from the 
pharmaceutical company that manufactures the drug that will be studied. If the company 
agrees with the scientific merits of the proposal, it may choose to provide some product 
(medicine or pure substance) and/or financial assistance. This support may include free 
donations of the drug (particularly important contribution when the drug is highly 
expensive). The company cannot, however, be involved in any way in the actual 
conduct of an investigator-initiated study.  The conclusions drawn from the study must 
be the independent judgment of the investigators. 
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c) Health economics and outcomes studies 
 
Health economics and outcomes studies usually are on the dependency of Market 
Access, especially in bigger pharmaceutical companies, and are critical to supporting 
the product value proposition. However, this analyses can also be performed by Medical 
Affairs for such purposes as: demonstrating the financial and quality-of-life impacts of a 
disease, the limitations of other therapies (including the existing standard of care), and 
the differentiating characteristics of a medicine/device in terms of cost and patient 
outcomes. Health economics and outcomes data are often critical to effective 
positioning with payers and health plans. They can also influence the prescription 
preferences of physicians.   
 
Health economics studies focus on the cost-benefit equation in purely financial terms.  
For example, they may evaluate the total cost per treatment episode of a company 
product, sometimes in comparison to the cost per treatment episode for another drug or 
therapeutic regimen, or if the use of the drug reduces the need for more expensive 
interventions such as hospitalizations. 
 
A drug with compelling proof of health economics or outcomes benefits is likely to be 
treated more favorably than a drug without it. This information can be used to influence 
payers and health authorities when they are making decisions about which drugs in a 
treatment category should have the best positioning on their formularies (the list of 
drugs they prefer to use). Medical Affairs teams can also use such evidence with 
prescribers, discussing the specific cost-benefit of a drug compared to other(s) in the 
treatment of a disease. 
 
Typically, these studies are performed as a retrospective analysis. The data utilized 
often comes from preexisting external resources, such as clinical studies, observational 
studies and prescription databases. Data sources may also include findings from the 
company’s own clinical studies. Preexisting data sets may not, however, answer all the 
treatment and outcomes questions that a pharmaceutical company or a payer 
considering its products would like to be addressed. In some cases, in order to gather 
specific information of interest, it may be necessary to conduct a prospective study and 
detailed analysis of the outcomes/results. 
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One way of conducting a prospective study is setting up a patient registry that screens 
future participants based on customized inclusion and exclusion criteria. The critical 
benefit of such analyses is the ability to specify the exact characteristics of study 
subjects and the precise data to be tracked. Unlike clinical studies, patient registries are 
solely observational in nature. They track the therapy provided to patients and their 
ongoing health status, but do not intervene to change healthcare practices. 
 
In some cases, analyses of patient registry data or of preexisting clinical study data may 
show the unmet needs of the treatment or minimize regulatory safety concerns. If 
unexpected health issues become apparent, however, regulators may change the labeling 
for the drug or drug class. In the absence of robust and reliable registrational data, 
clinicians who develop treatment guidelines may rely upon published health economics 
and outcomes studies as a basis to define the standard of care. 
 
 
d) Supporting the Brand team 
 
Medical Affairs is a valuable channel of clinical and scientific information to a 
pharmaceutical company’s commercial leadership. Although it is important to be clear 
that it is the Brand team, and not the Medical Affairs team, which defines promotional 
product messages, Medical Affairs can assist the Brand team by offering medical and 
scientific insights into the product’s value proposition.  
A huge quantity of data is typically generated in the course of a drug’s development.  
The Medical Affairs team synthesizes that data and provides commercial leaders with 
key findings in a way that they can easily understand without great depth of scientific or 
clinical expertise. 
 
The contributions of Medical Affairs often go beyond supplying the key clinical 
findings. Medical Affairs can offer feedback on the product’s strengths and 
differentiating attributes.  Its experts may also help guide discussions regarding the need 
for additional clinical studies and health economics and outcomes analyses, by 
identifying the data required to provide a compelling demonstration of key 
differentiating attributes; the gaps in currently available data; and the means of filling 
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those gaps. Medical Affairs may also offer special insight into the strengths and 
weaknesses of competing medicines. 
 
The Medical Affairs team may also be part of a promotional review committee, helping 
the Regulatory, Compliance and sometimes Access and Legal teams to verify the 
content accuracy of the messages developed by the brand team and their consistency 
with EMA-approved language in the label. 
 
In addition, the Medical Affairs team provides materials and information to support the 
training of the company’s “field force.”  The team creates scientific and medical content 
(and/or reviews the content created by outside vendors) in order to help the Brand/Sales 
team(s) develop course materials for the Sales Representatives.  The content is focused 
exclusively on scientific/medical aspects of the products and therapeutic area, not 
commercial messaging. 
 
At last, they can help put together Advisory Boards, meetings where a usually 
heterogeneous group of experts can freely discuss and provide credible advice on a 
predetermined subject (or simply to provide a more comprehensive overview of the 
environment), based on their clinical practice or scientific knowledge, in a closed 
setting. This can be very important for the Brand team, which is able to make 
adjustments to its strategy. 
 
 
e) Publication planning 
 
The Medical Affairs team is responsible for disseminating accurate, complete, and 
unbiased non-promotional information about company products and/or about the drug 
class and disease states that are of interest to the company (based on its current or future 
pipeline). This information may relate to research, preclinical, clinical, health 
economics, or outcomes data. 
 
The team designs and executes the publication plan for each product. The publication 
plan is a carefully synchronized effort to disseminate accurate disease state and product-
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related information in order to promote product understanding within the healthcare 
community and, as appropriate, product adoption.   
 
Although publication planning may be seen largely a matter of determining when and 
where to publish information about a product (When will the relevant data be available? 
When should publications and press releases be scheduled? What journal should be 
targeted? What assistance can we provide to the authors?), in fact it is a more strategic 
responsibility, with greater emphasis on defining the research data that must be 
generated to make the publication effort effective in conveying a product’s benefits.   
 
With respect to the publication planning strategy, Medical Affairs may ask: 
 What is needed to demonstrate the value proposition? 
 What are the data gaps? 
 How these can be overcome/answered? 
 What is our back-up strategy? 
 What are competitors’ data and strategies? 
 
With respect to tactical execution, Medical Affairs may assess: 
 When will data be available? 
 Which journals should be approached? 
 Is it better to publish in a subscription journal or go for open access? 
 When can final publication be expected? 
 
The Medical Affairs team also plays a role in medical writing related to company 
compounds and products, assisting with the translation of scientific and medical 
findings into various forms of written communication. Its involvement may begin as 
early as the research phase for a drug and continues across the product life-cycle. The 
team may draft or assist in the development of materials including the following: 
 Journal articles (manuscripts) 
 Abstracts (summaries of published articles) 
A CLOSER LOOK AT MEDICAL AFFAIRS 
 
Pedro Godinho (2014)   17 
 Posters (oversized summaries of preliminary study results, which key opinion 
leaders present at medical conferences and in other settings, in what are known 
as “poster sessions”) 
 Review articles (that synthesize all published research materials) 
 
While the Medical Affairs team may assist investigators on company-sponsored clinical 
studies with drafting and revising publications, a highly rigorous standard is applied to 
ensure that the named authors merit that status based on their contributions to a work.  
 
 
f) Relationships with Key Opinion Leaders (KOLs) 
 
Key opinion leaders (KOLs), also referred to as thought leaders, are highly respected 
experts in their clinical fields. Each therapeutic area typically has its own KOLs. Often, 
they are the foremost researchers in a particular therapeutic area. They may also be the 
editors or contributors to key journals in their area of specialization. Some KOLs are 
also involved in professional scientific societies. 
 
Regardless of their precise role, KOLs exert strong influence over other healthcare 
professionals. Their assessment of various treatment options carries great weight with 
community physicians deciding among therapies, and influences future prescribing 
patterns of physicians training in their institutions. It is therefore important to enlist the 
expertise of these KOLs in the development of new drugs. 
 
Pharmaceutical companies build and maintain KOL relationships for a variety of 
reasons, all related to their clinical expertise and the respect their peers have for their 
perspectives on a particular therapeutic area. What is the advantage for the company?  
 
 First, KOLs can offer insights into treatment issues and unmet needs in the 
therapeutic area, which may allow pharmaceutical companies to focus their 
clinical development efforts. 
 Second, KOLs may agree to contribute as investigators on clinical studies for 
company products, thereby increasing the impact of such studies on the 
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perceptions of other healthcare professionals. They may then agree to present 
findings from the clinical studies in which they were involved. 
 Third, KOLs provide disease-state education to their fellow physicians, building 
awareness of the need for diagnosis and the options available for treatment. 
 Finally, KOLs may educate peers/other physicians about the therapeutic options 
they consider best. Based on their independent medical analysis, KOLs may 
choose to recommend the class of drugs to which the company’s product 
belongs. 
 
Medical Science Liaisons (MSLs) within the Medical Affairs team are responsible for 
cultivating long-term relationships with key opinion leaders. Like Sales Representatives 
and Account Managers, MSLs work primarily out in the field. They routinely call upon 
medical centers, teaching/public/private hospitals and individual KOLs. In many cases, 
the KOLs are affiliated with one renowned medical institution.  
 
By fostering KOL relationships, MSLs can provide support for both non-registrational 
and registrational clinical studies, as they identify, evaluate, and help recruit potential 
study sites and also study investigators (physicians who may lead clinical studies at 
particular sites). 
 
Like other members of the Medical Affairs team, MSLs usually have extensive clinical 
or research experience in the therapeutic area with which they are associated. They have 
a medical degree, a doctorate in pharmacy, a doctorate in a field such as biology or 
epidemiology or some other degree reflecting deep expertise related to complex medical 
and scientific issues. 
 
Because MSLs communicate science in an unbiased manner, they are often recognized 
as “peers” by physicians, and their input and advice are highly valued. Healthcare 
professionals are often overwhelmed by people who want to speak with them about 
their products. For Sales Representatives, it is quite hard to win even a brief period of 
“face time” with a physician, particularly a KOL, while MSLs are more likely to gain 
access and their discussions with KOLs and physicians are often lengthy. 
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The success of a MSL in securing access is often tied directly to his or her demonstrated 
mastery of the latest research data related to a therapeutic area, disease state, and drug.  
Clinicians often welcome the opportunity to meet with people whom they perceive as 
unbiased experts who are equipped to respond to both on-label and off-label queries. 
 
In addition to conducting these routine “field” visits themselves, MSLs are also 
available as an expert resource for the Sales teams. As requested, they will present 
scientific and/or health economics data to key prescribers and payers. Typically, 
prescriber presentations take place at hospitals or in multi-client settings, such as 
conferences/congresses. In most cases, MSLs will not appear together with Sales 
Representatives, in order to eliminate any link to the commercial area, as well as to 
retain the independency of their role and the information they share. 
 
The MSLs are not only available for presentations but “on call” for expert consultation, 
when Sales teams or Account Managers need an interpretation of scientific or clinical 
information, as they are particularly well equipped to respond to complex queries. 
 
In some organizations, the MSLs can also interact with key customers at important 
hospitals/health authorities, such as clinical (medical) directors and formulary 
committees, or working in professional scientific societies, who are critical influencers 
regarding product inclusion in hospital/national formularies and guidelines. 
 
 
g) Medical Education and Training 
 
The Medical Affairs team may support both internal training and the sponsorship of 
external education programs.   
 
Internal training by Medical Affairs is not limited to education of team members within 
the function, teaching the scientific knowledge and the communications skills necessary 
to their roles but also teaching colleagues from Marketing, Sales team and enabling 
functions about a specific disease area/pathology or medicine, in order to increase their 
knowledge about it.  
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Sponsorship of external education programs is a critical responsibility of the Medical 
Affairs team. Medical Affairs sponsors continuing medical education (CME) programs, 
medical conferences, and symposia at which healthcare professionals in selected 
therapeutic areas gather. Medical education programs are selected based on relevance to 
therapeutic areas and disease states of importance to the company, as well as the interest 
key opinion leaders and other healthcare professionals have for the programs.  
 
Medical Affairs also sponsors speakers programs, at which healthcare professionals 
from outside the pharmaceutical company share information regarding the disease state, 
therapies, and ongoing research findings. All such programs should be a means of 
presenting an unbiased perspective on the disease states and available therapeutic 
options. 
 
A typical speakers program may consist of one or more key opinion leader(s) (doctor or 
pharmacist) meeting exclusively with fellow healthcare professionals. Possible topics of 
discussion include the merits of various therapies, current research findings from 
ongoing clinical studies or strategies on how to improve patient adherence to the 
medication. Some speakers programs, however, are modest community-based initiatives 
that provide information about treatment options to patients as well as healthcare 
professionals.   
 
To establish a greater separation of medical education from promotional efforts, there is 
a trend now that require Medical Affairs, and not Marketing, to control the budget and 
the ownership for these programs.  
 
Finally, although Medical Affairs can specify the general topic to be cover at a 
sponsored educational event, the team does not exert any control over the content of 
those presentations, and preserves the speakers’ freedom of speech.  
 
 
h) Market intelligence 
 
Medical Affairs has many opportunities to understand the clinical and market 
environment trends for company medicines and communicate that knowledge to 
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internal stakeholders so that all maintain a current understanding of the perspectives of 
key stakeholders. The Medical Affairs team maintains regular market awareness 
through: 
 close contact with healthcare professionals, that reveal their product questions, 
concerns, and preferences; 
 conversations in the “field” with key opinion leaders, who keep them updated of 
leading-edge investigations and unmet needs; 
 company-sponsored medical education programs; 
 feedback during presentations before medical audiences. 
 
Although this information is not gathered for commercial purposes, it is a valuable 
resource for commercial functions striving to understand market needs and concerns.  
This market intelligence is highly valuable to better understand the brand and the 
therapeutic area. 
 
 
i) Medical Information 
 
Responding to product-related information requests may also be a responsibility of the 
Medical Affairs function.  
 
Usually, this responsibility can be delegated on a specific team within Medical Affairs: 
the Medical Information group. This group responds to calls from other healthcare 
professionals, including physicians, nurses and pharmacists.  Less frequently, they also 
receive calls from patients. The calls are usually related to questions about appropriate 
use, risks, benefits, and other characteristics of company products. Many 
pharmaceutical and biotechnology companies also train their Sales Representatives to 
forward all off-label clinical questions arising during client calls to the Medical Affairs 
team or to the Medical Information group. 
 
For common queries, the Medical Information group may have “Frequently Asked 
Questions” scripts (internally pre-approved) to help them provide clear, consistent, and 
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accurate responses. Some companies may back their answers with a supporting letter 
and/or relevant literature.  
 
In larger organizations with an array of brands and/or brand indications, the Medical 
Information group can act as the “first line” of healthcare professionals that perform 
triage and answers more common questions, forwarding more complex questions to the 
Medical Affairs team, namely the Medical/Scientific Advisors, for a customized 
response. 
 
Calls from healthcare professionals to report adverse events in patients taking a drug are 
fielded by a separate function known as Pharmacovigilance or Drug Safety, which is 
responsible for reporting these events to regulators. During clinical studies, 
investigators report all such adverse events directly to the Drug Safety function.  After a 
drug is on the market, however, such reports may sometimes be sent to Medical 
Information, which then triages the calls to Drug Safety. Ideally, prior to forwarding the 
calls, the Medical Information captures detailed information about the reported adverse 
events to assist Drug Safety in categorizing them and assessing their seriousness. 
 
To be able to anticipate and respond effectively to queries, Medical Information needs 
to review and analyze available scientific and medical literature. To remain up to date, 
they monitor the literature on an ongoing basis. 
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V – MEDICAL AFFAIRS CORE COMPETENCES 
 
A Medical Affairs colleague must fulfill some minimum requirements in order to 
maximize his/her impact on customers, both internal and external. These requirements 
can fall in one of two major skills: scientific and personal. 
 
Scientific skills: 
 Know-how 
o Advanced knowledge of concepts and theories in the therapeutic area(s), 
including competitive landscape and current medical and scientific knowledge 
(e.g., disease states, product label, statistics interpretation) 
o Advanced knowledge of research, including but not limited to observational 
and clinical study design, hypothesis testing, basic statistical methods, clinical 
study analyses and basic understanding of other types of research (such as 
outcomes research and pharmacoeconomics) 
o Significant knowledge of the healthcare environment at local, regional and 
national level. 
 Customer focus 
o Identifies, develops, and maintains strong partnerships with regional and 
national medical experts, scientific societies and other decision makers 
o Builds and leverages a large network of contacts (key opinion leaders) 
o Acts and anticipates, by means of the customer, insights and needs 
o Knows how to optimally add value to a therapy area, product or service 
o Manages customer expectations by bearing in mind the business 
 Entrepreneurship 
o Innovative and proactive 
o Anticipates opportunities and solves problems 
 Results oriented  
o Action focused to achieve or exceed objectives 
o Business acumen 
o Uses opportunities to increase effectiveness and efficacy of services and 
processes 
 Networking 
o Has the ability to build and maintain a large network of contacts, internally and 
externally with a focus on information exchange 
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o Able to influence decision makers in profiling the services and products of a 
pharmaceutical company in the market 
 Cooperation/Working together  
o Works with colleagues or customers to achieve mutual goal 
 
Personal skills: 
 Engagement 
o Proactively engages with the organization demonstrating the value of the 
Medical Affairs role in achieving our business objectives 
o Exerts this competency positively in all circumstances, without compromising 
on his own personal values 
 Emotional intelligence 
o By having self and knowledge of others builds meaningful long term relations. 
The person has intrinsic interest in other people and acts in a way to gain trust 
that enables open communication 
 Integrity 
o Is an example of living the company’s values and procedures. 
o Takes and defends decisions being made and executes against them, even if 
they are not popular and controversial 
 Change agent 
o Acts positively and is open to change and uncertainties, without getting reactive 
or being paralyzed  
 Convincing others 
o Has strong written and oral communications skills and is able to present fair 
and balanced data effectively to both internal stakeholders and external 
customers, including medical experts and key decision-makers in small (1:1) or 
large meetings 
o Is able to motivate others 
 
These set of skills allow Medical Affairs teams to build and develop enduring peer-to-
peer relationships with healthcare professionals and institutions in order to create 
constructive and cross-functional partnerships with internal and external stakeholders. 
Acquired partnerships will generate customer insights and leverage business 
opportunities, providing medical/scientific support to the brand that is aligned and 
integrated in the overall brand strategy and clinical plans. 
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VII – LEVERAGING THE IMPORTANCE OF MEDICAL AFFAIRS 
 
Considering that the importance of Medical Affairs teams is growing, as more and more 
physicians recognize they are the most knowledgeable individuals to talk about a 
medicine within a pharmaceutical company, and they are independent, reliable and a 
trustworthy source of information, how can they reinforce its unbiased communication 
to make a significant difference in patients’ lives and strengthen the peer-to-peer 
relation with customers? The purpose is to create, demonstrate, and communicate the 
clinical value of medicines in a truthful, complete, balanced and unbiased fashion:  
• Enhancing knowledge of medicines and the associated therapeutic areas in 
which a company focus its research efforts. 
• Providing thorough understanding of its medicines: interpret emerging scientific 
trends, clinical data and the competitive landscape and align internal 
stakeholders on a balanced benefit/risk proposition. 
• Communicating to the medical and scientific communities in an accurate, fair 
and balanced manner about the benefits and the risks of the medicines, enabling 
prescribers and other healthcare decision-makers to take informed decisions with 
patients and use medicines safely and effectively. 
 
How will the Medical Affairs team demonstrate the value of the company’s medicines 
given the challenges posed by the market? It significantly depends on their ability to 
work in cross-functional teams: 
• Work cross-functionally with colleagues from Marketing, Sales, Regulatory and 
Access to guide the acquisition and integration of clinical data so that existing 
clinical evidence is communicated accurately, reflecting the value of the 
medicines; 
• Participate in regulatory strategy and engagement of regulatory agencies to 
ensure the clinical relevance of our medicines is well understood by regulators; 
communicate according to label; 
• Work in label development and the rationale for label changes throughout the 
medicine’s lifecycle; 
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• Work cross-functionally to establish publication planning in order to ensure 
timely and accurate dissemination of the company’s clinical studies data to the 
scientific community; 
• Partner actively with Market Access/Health Economics and Outcomes Research 
and other internal partners in designing payer strategies and engagement of 
payers to ensure the clinical value of our medicines is communicated properly 
throughout the lifecycle within the context of the existing and emerging 
treatment paradigm; 
• Provide customer insights to help inform the differentiation of the company’s 
medicines.  
 
How can the Medical Affairs team collaborate to impact positively the business of a 
pharmaceutical company? Medical Affairs teams are the interface between clinical 
development and clinical practice. From before proof-of-concept to the end of the 
lifecycle, they engage with and guide business development, research, and clinical and 
commercial development. They also: 
 Help to inform the right capital allocation decisions in the advancement of the 
lifecycle of the brands and the company’s pipeline; 
 Ensure launch readiness, organizing and training medical affairs colleagues and 
providing them with the tools to excel within the pre-, peri- and post-launch 
period; 
 Help the business grow by informing and aligning with cross-functional 
colleagues on what is needed to enhance the value through the generation of 
additional clinical study and real world data beyond registration throughout the 
medicine lifecycle; 
 Identify areas of unlocked value by gaining customer insights and thinking 
innovatively about current clinical data, treatment paradigms and healthcare 
environments. 
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VIII – CONCLUSION 
 
Medical Affairs is a division within a Medical Department of a pharmaceutical 
company, established to make possible the delivery of straight, truthful, complete and 
balanced information and the development of peer-to-peer interactions between 
collaborators from the company and healthcare professionals, mainly physicians.  
 
Its importance has arisen over the past years in response to external regulatory pressures 
to separate medical and commercial activities, improving the image/reputation of 
pharmaceutical industry. The Medical Affairs activities are all about healthcare 
professional education and working in partnership with them to achieve effective 
results, helping to address patients’ needs and the appropriate use of medicines. 
 
Medical Affairs colleagues are crucial for the pharmaceutical industry business as they: 
 
 Are experts in what regards providing medical/scientific support to 
marketing/access/sales;  
 Are able to deliver medical training to Sales Force or other internal colleagues 
about a specific disease/therapeutic area or about the medicines in the 
companies’ portfolio in order to increase their therapeutic skills and product 
knowledge; 
 Are competent collecting customer insights and feed it back into the 
pharmaceutical company to generate and leverage business opportunities;  
 Can support business decisions/brand activities by setting up and coordinating 
advisory boards;  
 Develop long-term relationships with external customers, namely key opinion 
leaders, scientific societies, health administrations, patient associations, 
investigators and hospital formulary committees; 
 Are responsible for developing medical educational programs and disease 
awareness activities (alone or in partnership with scientific societies and/or 
patient associations); 
 Are the contact point for investigator initiated research/studies (pre-clinical, 
clinical, non-interventional, etc); 
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 Are responsible, alone or in coordination with the medical information 
colleague, for answering to queries (from healthcare professionals or patients). 
 
Medical Affairs activities are present throughout different moments of a medicine life 
cycle, such as pre-, peri- and post-launch and even post-LOE (lost of exclusivity): 
 
 Prior to the commercialization of a new medicine, it is crucial to establish a 
KOL strategy to support the product launch. Medical Affairs colleagues must 
identify potential KOLs and foster interactions, providing available scientific 
information about the new medicine, including ongoing and upcoming studies. 
They should also perform disease awareness and discuss the appropriate 
treatment guidelines.  
 At the time of launch, they must effectively communicate the adequate use of 
the new drug, according to the approved indications, and address the results 
from clinical studies, adverse events profile, dosing regimen and specific drug 
attributes.  
 After the launch of a new drug, the Medical Affairs team can get in touch with 
key customers and retrieve feedback about the product, fine tune the 
communication of data about the new drug or addressing lacking information 
(developing phase IV studies, real world studies or investigator initiated 
research, that can be useful to differentiate the product from its competitors).  
 When the end of the drug’s life cycle is close, they are also responsible for 
putting in place a KOL disengagement strategy, whether transitioning the KOL 
to another business unit or progressively reducing the number of interactions 
with him/her, until a new drug is advancing on the pipeline and enters a phase 
II/III clinical development. 
 
Considering the growing importance of Medical Affairs teams, as both internal and 
external customers increasingly recognize they are the most knowledgeable individuals 
to talk about a medicine within a pharmaceutical company, and they are an independent, 
reliable and trustworthy source of information, capable of developing long-term, peer-
to-peer relationships with healthcare professionals, the value of such team for a 
pharmaceutical company cannot be dismissed. It will continue to positively impact the 
business. 
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